Again, you seem fixated on the broader market versus an individual, clinical stage biotech company where there is hardly any correlation between the two.
Short interest as of 31-July was 8.8 Days to Cover according to NASDAQ website. Being long the stock, I have no problem with a high short interest rate as it speaks to sentiment. As long as the Company continues to execute and move in a positive trajectory, incremental positive news would have a more material impact on the stock.
Although I get a whiff of moron from the poster you mentioned, he has one point. This investment is probably parked here until 2nd half 2015 when it has a good shot to shoot to the moon. The two possible variables otherwise:
1) unexpected drug failure
2) unexpected good news (partnership, quick drug approval, etc.)
Perhaps, but remember how negative sentiment is in the name versus where it was trading in anticipation of positive news earlier in the year, as well as Early 2013. I think when we start to see some more consistent positive news, you can see the stock sitting with a market cap of 500 - 600 million.
I would expect a meaningful move prior to 2H2015. To note, meaningful to me would be anything over 40% (but not in the 1000% like others might be expecting.